The completed phase I and Ib clinical trials show that single-dose and multi-dose furosemide tincture has good safety and tolerance for healthy subjects in China, and has no adverse side effects. According to the prospectus of Xianfeng Pharmaceutical Co., Ltd., Furetam tincture has the potential to attract more men with androgenetic alopecia compared with the existing treatment schemes, which is expected to change the market structure of androgenetic alopecia drugs.
Extended data
In 20 18, the clinical approval number of Furetidine Tincture was obtained in China and the United States respectively. At present, clinical phase I and Ib have been completed in China, and clinical phase I research has been completed in the United States. There are 102 subjects who participated in the clinical trial, and the corresponding PK and safety data have been obtained.
According to the latest statistics of the World Health Organization, one in six people in China has alopecia symptoms, and alopecia is the second largest social disease after obesity. Only finasteride and minoxidil are approved by FDA to treat AGA, but their efficacy and safety are limited. Furuitan tincture, as a brand-new compound independently developed, is expected to meet the new drug demand of alopecia patients.
Source of reference: Kaituo Pharmaceutical-Furuitai Tincture